Sage Therapeutics, Inc. (SAGE)
NASDAQ: SAGE · Real-Time Price · USD
6.59
+0.22 (3.45%)
Oct 11, 2024, 4:00 PM EDT - Market closed
Sage Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 97.24 | 86.46 | 7.69 | 6.31 | 1,114 | 6.87 | Upgrade
|
| Revenue Growth (YoY) | 837.55% | 1024.84% | 21.85% | -99.43% | 16123.06% | -92.39% | Upgrade
|
| Cost of Revenue | 304.95 | 358.39 | 326.98 | 283.72 | 293.28 | 369.22 | Upgrade
|
| Gross Profit | -207.7 | -271.94 | -319.29 | -277.41 | 820.92 | -362.35 | Upgrade
|
| Selling, General & Admin | 241.81 | 274.52 | 227.7 | 183.5 | 196.95 | 345.78 | Upgrade
|
| Operating Expenses | 241.81 | 274.52 | 227.7 | 183.5 | 196.95 | 345.78 | Upgrade
|
| Operating Income | -449.51 | -546.46 | -546.99 | -460.91 | 623.97 | -708.12 | Upgrade
|
| Interest & Investment Income | 37.37 | 38.74 | 14.19 | 2.88 | 9.6 | 27.8 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.15 | -0.38 | 0.02 | 0.13 | 0.25 | 0.08 | Upgrade
|
| EBT Excluding Unusual Items | -412.29 | -508.1 | -532.78 | -457.89 | 633.82 | -680.24 | Upgrade
|
| Merger & Restructuring Charges | -33.39 | -33.39 | - | - | -27.74 | - | Upgrade
|
| Pretax Income | -445.67 | -541.49 | -532.78 | -457.89 | 606.07 | -680.24 | Upgrade
|
| Net Income | -445.67 | -541.49 | -532.78 | -457.89 | 606.07 | -680.24 | Upgrade
|
| Net Income to Common | -445.67 | -541.49 | -532.78 | -457.89 | 606.07 | -680.24 | Upgrade
|
| Shares Outstanding (Basic) | 60 | 60 | 59 | 59 | 52 | 51 | Upgrade
|
| Shares Outstanding (Diluted) | 60 | 60 | 59 | 59 | 53 | 51 | Upgrade
|
| Shares Change (YoY) | 0.92% | 0.89% | 1.08% | 10.69% | 4.27% | 10.22% | Upgrade
|
| EPS (Basic) | -7.41 | -9.05 | -8.98 | -7.80 | 11.66 | -13.38 | Upgrade
|
| EPS (Diluted) | -7.41 | -9.05 | -8.98 | -7.80 | 11.43 | -13.38 | Upgrade
|
| Free Cash Flow | -373.87 | -541.14 | -460.97 | -378.55 | 663.94 | -534.46 | Upgrade
|
| Free Cash Flow Per Share | -6.22 | -9.04 | -7.77 | -6.45 | 12.53 | -10.51 | Upgrade
|
| Gross Margin | -213.59% | - | - | - | 73.68% | - | Upgrade
|
| Operating Margin | -462.25% | -632.08% | -7116.69% | -7306.74% | 56.00% | -10310.48% | Upgrade
|
| Profit Margin | -458.31% | -626.32% | -6931.88% | -7258.91% | 54.40% | -9904.46% | Upgrade
|
| Free Cash Flow Margin | -384.47% | -625.92% | -5997.57% | -6001.17% | 59.59% | -7781.84% | Upgrade
|
| EBITDA | -448.12 | -545.07 | -545.87 | -456.73 | 626.6 | -705.84 | Upgrade
|
| EBITDA Margin | - | - | - | - | 56.24% | - | Upgrade
|
| D&A For EBITDA | 1.39 | 1.39 | 1.12 | 4.18 | 2.63 | 2.28 | Upgrade
|
| EBIT | -449.51 | -546.46 | -546.99 | -460.91 | 623.97 | -708.12 | Upgrade
|
| EBIT Margin | - | - | - | - | 56.00% | - | Upgrade
|
| Revenue as Reported | 97.24 | 86.46 | 7.69 | 6.31 | 1,114 | 6.87 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.